Stealth Bio to cut jobs after FDA rejects therapy for rare disorder
PRIVATELY held Stealth BioTherapeutics said on Thursday the U.S. Food and Drug Administration had declined to approve its therapy for an ultra-rare condition called Barth Syndrome, prompting it to cut 30% of its workforce.
Barth syndrome, which is estimated to affect around 150 people in the United States, has no approved treatments. It typically affects boys and causes heart and muscle weakness, as well as delayed growth.
The FDA has asked the company to resubmit its application, which Stealth said would require more capital and prompted the job cuts.
The FDA did not respond to a Reuters request for comment
The therapy, elamipretide, has faced several setbacks, including the FDA's refusal to accept its marketing application in 2021. The company subsequently went private in 2022.
The latest setback comes after a 16.5-month review, during which the FDA extended its review from January to April to assess additional data. Last month, the regulator missed the extended deadline.
The company said the rejection came 'out of the blue'.
'We don't understand why it wasn't an approval, because there isn't really a request that we resubmit new data,' said CEO Reenie McCarthy.
'I think our frustration is: why didn't this come sooner?' McCarthy said.
In October, a panel of advisers to the FDA voted 10-6 in favor of the therapy.
Stealth had submitted data from a mid-stage trial that showed improvement in knee muscle strength by over 45%, which correlated with improvements on the six-minute walk test.
FDA raised the possibility of an accelerated approval based on the findings, but is hesitant to extend the pathway to critically ill newborns, who make up nearly two-thirds of the therapy's expanded access program participants.
The company said it will meet with the FDA next month.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
21 hours ago
- The Sun
Toshiba launches Malaysia's biggest-capacity refrigerator
TOSHIBA Sales & Services Sdn Bhd yesterday unveiled the NaturePure Series 820L refrigerator, certified by the Malaysia Book of Records as the biggest-capacity refrigerator in Malaysia. The NaturePure 820L refrigerator is Asean's first four-door, side-by-side refrigerator with a capacity exceeding 820 litres, sufficient for two weeks' food storage. Designed for multi-generational households, the appliance offers expansive and compartmentalised storage — ideal for organising everything from baby food and fresh produce to skincare items and frozen essentials. Powered by High-Capacity Technology, the NaturePure features super-thin insulation and component miniaturisation to maximise internal storage without increasing external size. Key features include: ● PureAir sterilisation system Eliminates 99.99% of bacteria and 99% of odours through hourly active purification — ideal for families with infants or health-sensitive needs. ● PureAir turbo mode Purifies three times faster than standard mode. Perfect for traditional or strong-smelling dishes. ● Pure ICE 3-Level System Delivers hygienic, odourless ice with FDA-certified water systems and integrated sterilisation. ● Magic 2 sizes ice maker Industry-first dual-mode ice maker producing cubed and half-cubed ice, up to 2kg in 95 minutes. ● Superior cooling with R290 refrigerant Offers 30% faster cooling while using eco-friendly refrigerants for reduced environmental impact. Expanding in Malaysia 'In 2025, Toshiba continues to chart strong growth by expanding our diversified product portfolio to reflect the evolving needs and values of today's consumers,' said Toshiba Sales & Services managing director Steven Yang. Toshiba Malaysia is targeting a 25% year-on-year growth compared to 2024, driven by rising consumer demand for technologically advanced and aesthetically refined home appliances. Yang said it targets to open one flagship store and establishing 50 Shop-in-Shop outlets by the end of 2025. There are 14 brand stores currently operating nationwide since Toshiba opened its first brand store in Kuala Lumpur in 2024. Under its 2025–2026 initiative, Toshiba Malaysia will focus on introducing industry leadership products and suite products. It has also earmarked an investment of not less than RM20 million per year for branding and digital marketing. Sustained market leadership across core categories As of the first quarter of 2025, Toshiba Malaysia has achieved significant market share across its key home appliance segments: ● Refrigerators: 16.7% (ranked second) ● Washing machines: 13.6% (ranked second) ● Microwave ovens: 10.5% (ranked fifth) Toshiba's market share continues to expand steadily across all product categories, driven by rising demand for smart, functional and energy-efficient home solutions. This results reflect the brand's continued strength in delivering lifestyle-enhancing solutions that resonate with Malaysian households. In the broader Asean region, Toshiba continues to deepen its market footprint, with Thailand maintaining strong performance and Japan, its home market, continuing to lead in brand dominance and customer loyalty. Looking ahead: Japandi-inspired product expansion Celebrating its 95th anniversary, Toshiba's innovation roadmap includes the continued rollout of its signature 'Japandi' Series — a harmonious fusion of Japanese craftsmanship and Scandinavian design sensibilities. Following the debut of the first Japandi refrigerator in 2024, Toshiba will expand the concept to include dishwashers, water purifiers and other home appliances — bringing seamless design and intuitive functionality into modern Malaysian homes.
Barnama
5 days ago
- Barnama
Fortrea, Emery Pharma Team Up On Rifampin Safety Testing For Clinical Trials
BUSINESS KUALA LUMPUR, June 25 (Bernama) -- Fortrea, a global contract research organisation (CRO), has announced a strategic collaboration with Emery Pharma to provide rapid impurity testing of rifampin used in drug-drug interaction (DDI) studies. In a statement, Fortrea said the partnership will enable testing for 1-methyl-4-nitrosopiperazine (MNP), a nitrosamine impurity, ensuring levels remain below the acceptable intake limit set by the United States Food and Drug Administration (FDA). Fortrea Chief Medical Officer and President of Clinical Pharmacology Services, Dr Oren Cohen said the partnership would help accelerate early-phase clinical trials by providing certified rifampin for use in DDI studies and enhance data quality. 'This collaboration reflects our shared commitment to smarter study design and greater participant safety,' he said. Meanwhile, Emery Pharma Chief Executive Officer, Dr Ron Najafi said the collaboration would contribute to safer and more efficient drug development, adding that the company specialises in solving complex analytical challenges in compliance with regulatory standards. Fortrea selected Emery Pharma based on its expertise in analytical and bioanalytical testing under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP) standards. The new testing service is now available to Fortrea customers involved in clinical pharmacology trials, with study designs tailored to FDA requirements. Rifampin, a widely used antibiotic and a preferred agent in DDI studies due to its safety and tolerability, had previously come under scrutiny after the FDA found that MNP levels in tested batches exceeded acceptable limits. However, the agency revised its guidance in 2023, allowing the continued use of rifampin under updated thresholds.
The Sun
5 days ago
- The Sun
FDA probes deaths linked to Sarepta's gene therapy for muscular dystrophy
THE U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics' gene therapy, Elevidys. In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. The patients who died were a 16-year-old, weighing 70 kilograms, and a 15-year-old, weighing 50 kilograms. Both boys were non-ambulatory and their deaths occurred within 90 days after treatment, the company said in an investor call last week. The two patients showed signs of acute liver failure and were hospitalized less than two months after treatment with Elevidys, the health regulator said on Tuesday. It added that it is evaluating the need for further regulatory action. Sarepta said in an email to Reuters, 'The FDA communication was triggered by our report to the FDA and our suggested update to the label to include information relating to the recent events.' The U.S. prescribing information for Elevidys warns of acute liver injury but does not mention liver failure or death. Elevidys, approved by the FDA in 2024 for ambulatory Duchenne muscular dystrophy patients aged four and older, is the only gene therapy available for the disease. It carries a known risk of liver damage and was conditionally approved for non-ambulatory patients despite failing to meet the main goal in a late-stage study. Sarepta said earlier this month it was investigating both cases independently and in relation to each other to identify any common risk factors. The company has suspended its Elevidys sales forecast for 2025, halted shipments to non-ambulatory patients and is working with regulators on a new treatment plan.
